Momenta Betting Biosimilar Push Will Put Balance Sheet Back in the Black

Momenta Pharmaceuticals will rely on milestone payments from three follow-on biologic projects with Baxter to return the company to profitability. Ongoing patent litigation, withering revenue streams and biosimilar development costs contributed to a net loss of $58.6 million in 2012. Momenta and Baxter are currently developing three biosimilar products, two targeting autoimmune and inflammatory indications (M923 and M834) and one in oncology (M511).
Drug Industry Daily